Product Description
A 5-aminoimidazole-4-carboxamide (AICA) riboside, a purine nucleoside analog, and a nucleotide biosynthesis precursor with B cell pro-apoptotic activity. Following cellular uptake, acadesine is phosphorylated to AICA ribotide (ZMP), which mimics 5'-adenosine monophosphate (AMP). Both AMP-activated protein kinase (AMPK) and AMPK kinase (AMPKK) are activated by ZMP, which appears to be necessary for the induction of apoptosis.
Mechanisms of Action: AMPK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ADVANCELL
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pulmonary Infarction|Ventricular Dysfunction, Left|Stroke|Myocardial Infarction|Coronary Artery Disease
Phase 2: Acute Myeloid Leukemia|Febrile Neutropenia|Lymphocytic Chronic B-Cell Leukemia|Chronic Myelomonocytic Leukemia|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Myelodysplastic Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12618001612202p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Shoulder Pain|Musculoskeletal Pain |
2018-11-30 |
|||
2012-003120-21 |
2012-003120-21 | P2 |
Active, not recruiting |
Myelodysplastic Syndrome |
2015-04-15 |
2022-03-13 |
Treatments |
|
NCT01813838 |
Acadesine | P2 |
Terminated |
Chronic Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia|Acute Monocytic Leukemia|Myelodysplastic Syndrome|Febrile Neutropenia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia |
2013-06-01 |
2019-03-19 |
Treatments |
|
NCT00559624 |
ATH001-CLN01 | P2 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2010-12-01 |
2019-03-22 |
Treatments |
|
2007-002557-23 |
2007-002557-23 | P2 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2009-11-02 |
2022-03-12 |
Treatments |
|
2008-004881-16 |
RED-CABG Trial | P3 |
Terminated |
Coronary Artery Disease |
2010-10-04 |
2022-03-12 |
Treatments |
|
NCT00872001 |
RED-CABG | P3 |
Terminated |
Myocardial Infarction|Stroke|Ventricular Dysfunction, Left|Pulmonary Infarction |
2010-10-01 |
2022-05-04 |
Primary Endpoints|Treatments |